Research programme: cell permeable peptide fusion proteins - Portage Pharmaceuticals

Drug Profile

Research programme: cell permeable peptide fusion proteins - Portage Pharmaceuticals

Alternative Names: Cell permeable peptide platform technology - Portage Pharmaceuticals

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Portage Biotech
  • Class Gene therapies; Nucleotides; Peptide vaccines; Recombinant fusion proteins
  • Mechanism of Action NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Eye disorders; Neurological disorders

Most Recent Events

  • 26 Apr 2015 Portage Pharmaceuticals announces intention to submit IND for PPL 003
  • 14 Jul 2014 Cell permeable peptide fusion proteins from Portage Pharmaceuticals' pipeline are available for licensing after proof of concept trial
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top